[Cefazolin. 3. Double blind controlled trial in urinary tract infections].
D000328:Adult; D002509:Cephaloridine / Q000008:administration & dosage / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D013293:Enterococcus faecalis / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007711:Klebsiella pneumoniae; D008826:Microbial Sensitivity Tests; D008837:Micrococcus / Q000187:drug effects; D008875:Middle Aged; D011512:Proteus Infections / Q000188:drug therapy; D011513:Proteus mirabilis / Q000187:drug effects; D011514:Proteus vulgaris / Q000187:drug effects; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D002509:Cephaloridine